Targeted therapy and immunotherapy with or without radiation for liver cancer
Part of Cancer, Digestive system clinical trials.
This study looks at combining targeted therapy and immunotherapy, with or without radiation, for people with advanced liver cancer that has spread or can't be treated with standard methods like surgery or embolization. It aims to find out if adding radiation improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of hepatocellular carcinoma (a common type of liver cancer).
- You received targeted therapy and immunotherapy at a specific hospital (Zhongshan Hospital, Fudan University) between 2017 and 2023.
- Your liver cancer must be at an advanced stage, such as having spread to blood vessels or other organs, or being too large or risky for surgery or other local treatments.
- Your doctor must have complete medical records and follow-up information for you.
- You must agree to donate biological samples (like blood or tissue) for future research.
- You cannot have another type of liver cancer (like cholangiocarcinoma) or a history of other cancers in the last 5 years, with a few exceptions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (ipilimumab and nivolumab) plus targeted radiation (SBRT) for people with liver cancer that is advanced but has not spread outside the liver. The goal is to see if this approach can shrink tumors and make them easier to remove with surgery.
This study looks at how well different combinations of interventional procedures (like TACE) and systemic treatments (like targeted therapy or immunotherapy) work for liver cancer. It uses real-world data to find which combinations might be best for different patients.
This study is testing whether combining targeted therapy with immunotherapy can help people with advanced liver cancer that cannot be surgically removed. The goal is to see if this combination treatment is safe and effective.
This trial tests whether using immunotherapy alone works as well as immunotherapy combined with radiation for liver cancer that has spread into major blood vessels. The goal is to find the best treatment option for people with this specific type of advanced liver cancer.
This trial tests whether adding targeted radiation therapy can help people with liver cancer that cannot be surgically removed. It is for people who have already received a combination of TACE, lenvatinib, and sintilimab and whose tumors have not grown.
This trial tests whether combining radiation (IMRT) with two drugs—camrelizumab (an immunotherapy) and apatinib (a targeted therapy)—before surgery can help people with liver cancer that has spread to the main blood vessel of the liver (portal vein). The goal is to shrink the tumor and improve surgical outcomes.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.